Net loss for the three months ended June 30, 2025, was $41.6 million or $0.49 per basic and diluted share, compared to a net loss of $28.7 million, or $0.38 per basic and diluted share, for the three ...

YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerabil ...

In another study, published in Cell in June, researchers treated a patient with systemic sclerosis, a rare and serious ...

Chris Hemsworth has opened up about how learning of his heightened genetic risk for Alzheimer’s disease has reshaped the way he approaches health, work, and family. The 41-year-old Thor actor first ...

This past June, researchers congregated at the Smithsonian Marine Station to catalogue the vast diversity of tiny animals ...

Nitinol Medical Device Market Gains Momentum as Shape-Memory Innovation Transforms Medical Technology ...

Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy ...